Vor Biopharma Inc. is a clinical-stage biotechnology company that develops targeted therapies for severe diseases. The company historically focused on a "shield and strike" platform utilizing engineered hematopoietic stem cells (eHSCs) and CAR-T therapies for hematological malignancies such as acute myeloid leukemia. In 2025, Vor Biopharma strategically pivoted its operations to focus on autoimmune diseases, winding down its oncology programs. The company's lead clinical program is now telitacicept, an in-licensed dual BAFF/APRIL inhibitor fusion protein being evaluated for conditions including Myasthenia Gravis and primary Sjögren's Disease. Headquartered in Cambridge, Massachusetts, the company operates primarily in the United States while leveraging global licensing partnerships to expand its therapeutic pipeline.
